Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, Ariyaratne PN, Takahashi N, Sawada K, Fei Y, Soh S, Lee WH, Huang JW, Allen JC Jr, Woo XY, Nagarajan N, Kumar V, Thalamuthu A, Poh WT, Ang AL, Mya HT, How GF, Yang LY, Koh LP, Chowbay B, Chang CT, Nadarajan VS, Chng WJ, Than H, Lim LC, Goh YT, Zhang S, Poh D, Tan P, Seet JE, Ang MK, Chau NM, Ng QS, Tan DS, Soda M, Isobe K, Nöthen MM, Wong TY, Shahab A, Ruan X, Cacheux-Rataboul V, Sung WK, Tan EH, Yatabe Y, Mano H, Soo RA, Chin TM, Lim WT, Ruan Y, Ong ST.

Nat Med. 2012 Mar 18;18(4):521-8. doi: 10.1038/nm.2713.

PMID:
22426421
2.

Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia.

Mohan BP, How GF, Loh Y, Linn YC.

Br J Haematol. 2012 Apr;157(1):131-2. doi: 10.1111/j.1365-2141.2011.08910.x. Epub 2011 Nov 3. No abstract available.

PMID:
22050655
3.

Acquisition of the novel ABL kinase domain mutation T315L in a relapsed Philadelphia-positive acute lymphoblastic leukemia patient.

How GF, Müller MC, Lim LC.

Leuk Res. 2012 Jan;36(1):e20-1. doi: 10.1016/j.leukres.2011.08.011. Epub 2011 Sep 6. No abstract available.

PMID:
21899886
4.

Outpatient-based therapy of oral fludarabine and subcutaneous alemtuzumab for asian patients with relapsed/refractory chronic lymphocytic leukemia.

Hwang WY, Dearden C, Loh YS, Linn YC, Tien SL, Teoh GK, How GF, Heng KK, Goh YT, Lee LH.

Adv Hematol. 2009;2009:547582. doi: 10.1155/2009/547582. Epub 2008 Feb 25.

5.
6.

Umibilical cord blood stem cell from unrelated donors is a feasible alternate stem cell source for transplant in patients with genetic diseases.

Tan PL, Shek PC, Lim LC, How GF, Tan P, Yeoh AE, Quah TC.

Ann Acad Med Singapore. 2004 Sep;33(5 Suppl):S82-3. No abstract available.

PMID:
15651225
7.
8.

Molecular and phenotypic spectrum of de novo Philadelphia positive acute leukemia.

Lim LC, Heng KK, Vellupillai M, Tan LT, Boey BC, Lau LC, How GF.

Int J Mol Med. 1999 Dec;4(6):665-7.

PMID:
10567681
9.

Two patients with novel BCR/ABL fusion transcripts (e8/a2 and e13/a2) resulting from translocation breakpoints within BCR exons.

How GF, Lim LC, Kulkarni S, Tan LT, Tan P, Cross NC.

Br J Haematol. 1999 May;105(2):434-6.

PMID:
10233416
10.

Chronic myeloid leukemia with e19a2 (c3a2) BCR/ABL fusion junction--is it truly a benign disease?

How GF, Tan LT, Lim LC.

Leukemia. 1998 Jul;12(7):1166-7. No abstract available.

Supplemental Content

Loading ...
Support Center